公开(公告)号：US20220096410A1

公开(公告)日：2022-03-31

申请号：US17422057

申请日：2020-01-09

申请人： Ken-ichi YAMADA ,  FUSO PHARMACEUTICAL INDUSTRIES, LTD.

发明人： Ken-ichi YAMADA ,  Saki SHINTO ,  Minato ISHIDA ,  Keiichi YAMAMOTO

IPC分类号： A61K31/198 ,  A61K45/06 ,  A61P27/02

摘要： The present invention may provide a pharmaceutical composition for intraocular administration or oral administration, for preventing or treating a retinal disease (such as age-related macular degeneration), or suppressing a progression of the disease in a subject in need of treatment, the composition comprising an effective amount of one or more compounds selected from the following group, and a pharmaceutically acceptable carrier; and a method therefor, a group consisting of apomorphine, eseroline, ethoxyquin, methyldopa, olanzapine and indapamide.